KMDA Kamada Ltd.

NASDAQ
$7.58

Kamada Ltd. (KMDA) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.9% since its last earnings release on August 12, 2026.

Kamada Beat Consensus Estimates, Reaffirms
Wednesday, August 12, 2026 · 7:05 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs $0.13
Rev est $54.75M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.14

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kamada Ltd.

Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops and produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Sector

Healthcare

Industry

Biotechnology